NCT01245582

✓ Unanimous Initial: other Requery: other — This is a palliative oncology trial with an infusion delivered every 2 weeks; this treatment cycle typically takes place in an outpatient clinic or ambulatory day hospital setting rather than requiring inpatient hospital admission.

✓ Unanimous Initial: other Requery: other — This is an outpatient oncology treatment study where patients receive oral medications at home and periodic intravenous infusions at outpatient clinics, not requiring hospitalization.

✓ Unanimous Initial: hospital Requery: other — The trial involves drug delivery through both oral and intravenous routes, with no specific mention of hospitalization or home care, suggesting an outpatient or clinic-based setting.

✓ Unanimous Initial: no Requery: no — The intervention is a single-modality pharmacologic treatment combining multiple chemotherapy drugs (oxaliplatin, capecitabine, and sorafenib) without components from different categories such as behavioral or educational interventions.

✓ Unanimous Initial: no Requery: no — This is a pharmacologic intervention comparing a combination of three anticancer drugs (oxaliplatin, capecitabine, sorafenib) versus sorafenib alone, which represents a single intervention type despite using multiple medications.

✓ Unanimous Initial: yes Requery: no — The trial involves combining pharmacologic agents only (oxaliplatin, capecitabine, sorafenib), which are different drugs but all within the same pharmacologic category.